Figures & data
Table 1 Baseline characteristics
Table 2 Blood analysis
Figure 1 Laboratory testing.
Abbreviations: cMRI, cardiac magnetic resonance imaging; LDL, low-density lipoprotein; MDRD, modified diet in renal disease; t0, baseline; t12, at 12 months; wtATTR-CM, wild-type transthyretin amyloid cardiomyopathy; NT-proBNP, N-terminal prohormone of brain natriuretic peptide.
![Figure 1 Laboratory testing.](/cms/asset/6aac2c85-5709-4739-8817-19f12d76d46c/dddt_a_12188353_f0001_b.jpg)
Figure 2 Echocardiography findings.
Abbreviations: t0, baseline; t12, at 12 months; wtATTR-CM, wild-type transthyretin amyloid cardiomyopathy.
![Figure 2 Echocardiography findings.](/cms/asset/4974341d-038d-44a1-9756-82bceb3bbf52/dddt_a_12188353_f0002_b.jpg)
Table 3 Echocardiography
Table 4 Cardiac magnetic resonance imaging
Figure 3 cMRI findings.
Abbreviations: cMRI, cardiac magnetic resonance imaging; LV, left ventricular; LVEF, LV ejection fraction; t0, baseline; t12, at 12 months; wtATTR-CM, wild-type transthyretin amyloid cardiomyopathy.
![Figure 3 cMRI findings.](/cms/asset/74fae64a-ae89-4833-8b12-c668064e0f5a/dddt_a_12188353_f0003_b.jpg)
Figure 4 LV myocardial mass (A) and LVEF (B) of patients with wtATTR-CM who underwent assessment by cMRI with green tea extract consumption for longer than 1 year.
![Figure 4 LV myocardial mass (A) and LVEF (B) of patients with wtATTR-CM who underwent assessment by cMRI with green tea extract consumption for longer than 1 year.](/cms/asset/8c6c3ccb-197e-4098-be5f-9bd9ed7c532c/dddt_a_12188353_f0004_b.jpg)